Related Experiment Video
Updated: Jun 27, 2026
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with
Shang-Gin Wu1, Yih-Leong Chang, Ya-Chieh Hsu
1Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Background:
Epidermal growth factor receptor (EGFR) mutations are usually detected in lung adenocarcinoma and are associated with a response to EGFR tyrosine kinase inhibitors (TKIs). However, not all EGFR mutations have similarly high clinical response rates. This study aimed to investigate the clinical characteristics and response to gefitinib in lung adenocarcinoma patients with complex EGFR mutations.
Materials And Methods:
Three hundred thirty-nine specimens of lung adenocarcinoma from patients treated with gefitinib were collected for EGFR sequencing. Nineteen patients with complex EGFR mutations were enrolled for the study after excluding three patients with the EGFR T790M mutation, which confers resistance to gefitinib.
Results:
Among the 19 patients, 12 had complex mutations with the classical mutation pattern (L858R or deletion in exon 19). When compared with those without the classical mutation pattern, patients with this mutation pattern had a higher response rate (83% versus 29%), longer progression-free survival duration (median, 12.7 months versus 4.9 months), and longer overall survival time (median, 24.7 months versus 12.3 months) after gefitinib treatment. Comparing patients harboring complex EGFR mutations with a classical mutation pattern with those harboring single classical mutations, there were no statistical differences in the response rate (83% versus 73%), progression-free survival time (median, 12.7 months versus 8.1 months,) or overall survival time (median, 24.7 months versus 16.4 months).
Conclusion:
Patients with complex EGFR mutations with the classical mutation pattern had the same response rate, progression-free survival duration, and overall survival time as those with single classical mutations. EGFR TKIs may be the choice of treatment for this type of lung adenocarcinoma.
Insights
Complex epidermal growth factor receptor (EGFR) mutations with classical patterns in lung adenocarcinoma show similar responses to EGFR tyrosine kinase inhibitors (TKIs) as single mutations. This suggests EGFR TKIs are a viable treatment option for these patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Epidermal growth factor receptor (EGFR) mutations are key drivers in lung adenocarcinoma, influencing response to EGFR tyrosine kinase inhibitors (TKIs).
- Not all EGFR mutations confer similar clinical efficacy with EGFR TKIs.
- Complex EGFR mutations require further investigation for treatment stratification.
Purpose of the Study:
- To investigate the clinical characteristics and treatment response to gefitinib in lung adenocarcinoma patients with complex EGFR mutations.
- To compare outcomes between complex EGFR mutations with and without classical mutation patterns.
- To evaluate the efficacy of EGFR TKIs in complex EGFR mutation cases.
Main Methods:
- EGFR sequencing was performed on 339 lung adenocarcinoma specimens from patients treated with gefitinib.
- Nineteen patients with complex EGFR mutations were identified and analyzed, excluding those with the T790M resistance mutation.
- Clinical characteristics and treatment outcomes were compared based on mutation patterns.
Main Results:
- Complex EGFR mutations with classical patterns (L858R or exon 19 deletion) showed significantly higher response rates (83% vs. 29%), longer progression-free survival (12.7 vs. 4.9 months), and overall survival (24.7 vs. 12.3 months) compared to those without classical patterns.
- No statistical differences in response rate, progression-free survival, or overall survival were observed between complex EGFR mutations with classical patterns and single classical mutations.
- EGFR TKI treatment demonstrated efficacy in patients with complex EGFR mutations.
Conclusions:
- Complex EGFR mutations with classical patterns exhibit similar clinical outcomes to single classical mutations when treated with EGFR TKIs.
- EGFR TKIs represent a potential therapeutic strategy for lung adenocarcinoma patients with complex EGFR mutations and classical patterns.
- Further research into complex EGFR mutations may refine personalized treatment approaches in lung adenocarcinoma.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...